The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.

Nobuki Furubayashi,Akinori Minato,Takahito Negishi,Naotaka Sakamoto,Yoohyun Song,Yoshifumi Hori,Toshihisa Tomoda,Mirii Harada,Shingo Tamura,Hiroki Kobayashi, Yamato Wada,Kentaro Kuroiwa,Narihito Seki,Naohiro Fujimoto,Motonobu Nakamura

OncoTargets and therapy（2022）

引用 0|浏览2

暂无评分

摘要

Pembrolizumab for advanced UC demonstrated similar changes in the eosinophil count, efficacy and toxicity in both older and younger patients. In patients with a poor PS, although toxicity was significantly lower, survival was significantly worse, and neither an increase in REC nor a decrease in NER were observed, but these values showed significant changes in patients with a good PS.

查看译文

关键词

age,immune-related adverse events,neutrophil-to-eosinophil ratio,pembrolizumab,performance status,relative eosinophil count,urothelial carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要